Results 161 to 170 of about 636,170 (221)

[Efficacy and safety analysis of BTK inhibitors combined with R-CHOP regimen in newly diagnosed double-expressor diffuse large B-cell lymphoma]. [PDF]

Zhonghua Xue Ye Xue Za Zhi
Lu JB, Cao L, Liu HL, Miao Y, Shen HR, Xia Y, Yin H, Cheng YX, Li JY, Fan L.   +9 more
europepmc   +1 more source

Case report: BTK inhibitors is effective in type II mixed cryoglobulinemia with wild-type MyD88. [PDF]

Front Immunol
Xu M, Xu Y, Yuan L, Shang D, Chen R, Liu S, Li Y, Liu A, Liu R, Wang Q, Ding T, Xie Q, Hao CM.   +12 more
europepmc   +1 more source

Identification of Potential Nontoxic Human <i>BTK</i> Inhibitors through an Integrated Deep Learning and Structure-Based Drug Repositioning Strategy. [PDF]

ACS Omega
Iqbal MW, Sun X, Yuan Q.
europepmc   +1 more source

Treatment of relapsed/refractory chronic lymphocytic leukemia with Zanubrutinib after progressing on other BTK inhibitors. [PDF]

Leuk Res Rep
Nwankwo N, Reddy A, Kumar S, Zafar M.
europepmc   +1 more source

Development of combination therapies with BTK inhibitors and dasatinib to treat CNS-infiltrating E2A-PBX1+/preBCR+ ALL. [PDF]

Blood Adv
Gentile G, Poggio T, Catalano A, Voutilainen M, Lahnalampi M, Andrade-Martinez M, Ma T, Sankowski R, Goncharenko L, Tholen S, Han K, Morgens DW, Prinz M, Lübbert M, Engel S, Hartmann TN, Cario G, Schrappe M, Lenk L, Stanulla M, Duyster J, Bronsert P, Bassik MC, Cleary ML, Schilling O, Heinäniemi M, Duque-Afonso J.   +26 more
europepmc   +1 more source

How I use genomics and BTK inhibitors in the treatment of Waldenström macroglobulinemia.

Blood
Treon SP, Sarosiek S, Castillo JJ.
europepmc   +1 more source

Btk Inhibitors: A Medicinal Chemistry and Drug Delivery Perspective

International Journal of Molecular Sciences, 2021
In the past few years, Bruton's tyrosine Kinase (Btk) has emerged as new target in medicinal chemistry. Since approval of ibrutinib in 2013 for treatment of different hematological cancers (as leukemias and lymphomas), two other irreversible Btk ...
Chiara Brullo, Andrea Spallarossa, Carla Villa   +2 more
exaly   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

On-Target BTK Mutations Promote Resistance to Noncovalent BTK Inhibitors

Cancer Discovery, 2022
Abstract Resistance to noncovalent BTK inhibitors is mediated by non-C481 BTK and PLCγ2 mutations.
openaire   +2 more sources

The role of noncovalent BTK inhibitors in the era of covalent BTK inhibitors.

Clinical advances in hematology & oncology : H&O
Despite significantly improving outcomes in patients with B-cell malignancies, covalent Bruton tyrosine kinase (BTK) inhibitors are limited by toxicities and the development of resistance. Some toxicities can be life-threatening, such as cardiotoxicity.
Fateeha, Furqan, Nirav N, Shah
openaire   +1 more source